• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Health Care Reform And Women: A Comparison Of The ACA And The AHCA
By Susan Blumenthal, M.D. and Alexandrea Adams The recent commemoration of National Women’s Health Week provided an important time to mark the progress that has been made in advancing women’s health over the past two decades and to highlight what more needs to be done to achieve women’s health equity in America. Historically, women have experienced discrimination in health care despite making 80 percent of health care decisions for their families, using more medical services than men, and suffering greater disability from chronic disease. Before the mid 1990’s, women were often excluded as subjects ...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Next-Generation Cancer Immunotherapy Targeting Glypican-3
This study was supported in part by the National Cancer Center Research and Development Fund (25-A-7 and 28-A-8); Health and Labor Science Research Grants for Clinical Research, Japan; and joint research funding from Takeda Pharmaceutical Co, Ltd.; Noile-Immune Biotech Inc.; Ono Pharmaceutical Co., Ltd.; BrightPath Biotherapeutics Co., Ltd.; and Sysmex Co., Ltd. This study was performed as part of a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan. Conflict of Interest Statement TN, TS, and TY ...
Source: Frontiers in Oncology - April 9, 2019 Category: Cancer & Oncology Source Type: research

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Ad hoc announcement pursuant to Art. 53 LR Roche ’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigatingTecentriq plusAvastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of recurrence-free survivalNew adjuvant treatments are urgently needed as an estimated 70-80% of people with early-stage HCC experience disease recurrence following surgery1Data will be discussed with health authorities globally, including the US Food and Drug Administration and the European Medicines Agency to inform the next regulatory steps, and presented at an upcoming medical meetingBasel, 19 January 2023 - Roche (SIX: RO, ROG;...
Source: Roche Media News - January 19, 2023 Category: Pharmaceuticals Source Type: news

Community-Based Strategies to Improve Screening, Diagnosis and Linkage to Care for Patients with Chronic Hepatitis B
AbstractPurpose of ReviewChronic hepatitis B (CHB) places 3.5% of the world population at risk of dying from liver failure or liver cancer. Effective antiviral therapies can change disease outcomes, provided that CHB screening and linkage to care can be delivered at population level, to reach the vast numbers of undiagnosed people. We therefore reviewed the experience of community-based CHB screening programs reported in the English literature since 2014.Recent FindingsTwenty papers met eligibility criteria and only one originated from a low-income country. The two randomised studies found that culturally tailored hepatiti...
Source: Current Hepatitis Reports - July 23, 2019 Category: Infectious Diseases Source Type: research

Community-Based Services to Improve Testing and Linkage to Care Among Non-U.S.-Born Persons with Chronic Hepatitis B Virus Infection - Three U.S. Programs, October 2014-September 2017.
This report describes each program's operational services and partnerships with primary care centers, community-based organizations, and public health departments to recruit non-U.S.-born persons for HBV testing using the hepatitis B surface antigen (HBsAg) and link those whose test results were positive to HBV-directed care (medical visit attendance with monitoring of HBV DNA and liver enzyme tests). Among 10,152 program participants, 757 (7.5%) were HBsAg-positive, indicative of chronic HBV infection; among these, 643 (85%) attended ≥1 medical visit, 587 (78%) received HBV-directed care, and 137 (18%) were prescribed a...
Source: MMWR Morb Mortal Wkl... - May 18, 2018 Category: Epidemiology Authors: Harris AM, Link-Gelles R, Kim K, Chandrasekar E, Wang S, Bannister N, Pong P, Chak E, Chen MS, Bowlus C, Nelson NP Tags: MMWR Morb Mortal Wkly Rep Source Type: research

Diagnosis, Management, and Prevention of Hepatitis B Reactivation
Abstract Chronic hepatitis B (CHB) is a global public health problem and is the leading cause of cirrhosis and liver cancer worldwide. Despite significant morbidity and mortality of CHB, there remains lack of knowledge and awareness in screening patients at risk. HBV reactivation is well documented in patients previously exposed to HBV receiving immunosuppressive agents and is characterized by a rise in serum HBV DNA with ALT elevation. The delayed recognition of reactivation can lead to significant clinical consequences, including liver failure and death, and can be prevented with antiviral treatment. The challen...
Source: Current Hepatitis Reports - August 1, 2015 Category: Infectious Diseases Source Type: research

Pages: 1  2